New hope for tough cancers: experimental drug targets HER3 in advanced tumors
NCT ID NCT06956690
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 33 times
Summary
This study tests an experimental drug called HMBD-501 in 180 adults with advanced solid tumors (melanoma, lung, or breast cancer) that have a protein called HER3 on their cells and have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then checking if the drug can shrink tumors. The goal is to control the disease, not cure it, as patients may need ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGLa Jolla, California, 92093, United States
Contact Email: •••••@•••••
-
Research Site
RECRUITINGIndianapolis, Indiana, 46250, United States
Contact Email: •••••@•••••
-
Research Site
RECRUITINGFarmington Hills, Michigan, 48334, United States
Contact Email: •••••@•••••
-
Research Site
RECRUITINGDallas, Texas, 75230, United States
Contact Email: •••••@•••••
-
Research Site
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
Research Site
WITHDRAWNCampbelltown, New South Wales, 2560, Australia
-
Research Site
WITHDRAWNMiranda, New South Wales, 2228, Australia
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.